# A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

> **NCT03589326** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Takeda** · enrollment: 245 (actual)

## Conditions studied

- Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)

## Interventions

- **DRUG:** Ponatinib
- **DRUG:** Imatinib
- **DRUG:** Vincristine
- **DRUG:** Dexamethasone
- **DRUG:** Cytarabine
- **DRUG:** Methotrexate
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT03589326
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-10-04
- **Primary completion:** 2022-08-12
- **Final completion:** 2027-07-31
- **Target enrollment:** 245 (ACTUAL)
- **Last updated:** 2025-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03589326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03589326, "A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03589326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*